Biotech startup Orna Therapeutics has cut more jobs in its second round of layoffs in the last ... Bristol Myers Squibb, ...

Based outside Boston, MilliporeSigma was formed after Merck KGaA acquired St. Louis-based Sigma-Aldrich Corp. for $17 billion ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Two days after a seismic election that many saw as a referendum on gender progress in the United States, 9,000 women ...

Germany's Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business.

Merck KGaA’sMRK-1.94%decrease; red down pointing triangle shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other Dow stocks. Since its introduction in 1896, the Dow Jones has undergone significant ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

Merck's Q3 sales reached $16.7 billion, a 4% YoY increase, beating the $16.5 billion consensus estimate. Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition and likely see sales slide noticeably. There aren't any obvious ...